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Review
In the past 5 years, nearly half of China’s regional blood 
centers have carried out a rare blood screening program 
aimed at elucidating the genetic characteristics of blood 
groups in the Chinese population and identifying high-
prevalence antigen-negative blood donors. The Rare Blood 
Bank of China was established through serological screening 
and genetic testing, and currently more than 1300 rare blood 
donors have been identified. A total of 79 blood units of 
various rare blood types have been transfused in hospitals 
within the past 5 years.
In clinical transfusion, it is important to choose antigen-
matched blood for patients to avoid alloimmunization. More 
than 300 blood group antigens are expressed on the human 
erythrocyte membrane; they are immunogens that can induce 
antibodies that can potentially cause adverse transfusion 
reactions. In addition to the challenge of matching for such 
a large number of antigens, the expression of these antigens 
differs among various populations, making it even more 
difficult to match donors to patients.
Screening Program for Rare Blood in China
Since 2003, screening donors for rare blood has been 
carried out as a routine process at the Institute of Transfusion 
of the Shanghai Blood Center. In 2007, a plan for establishing 
a national rare blood bank was included in the Blood Safety 
Program of Public Health special project by the Chinese 
Ministry of Health. Currently, there are 14 regional blood 
centers in China that carry out donor screening throughout 
the year and provide the obtained rare blood to the Shanghai 
Blood Center.
In screening for rare blood in China, we first test donor 
samples negative for high-prevalence antigens that are difficult 
to match in clinical transfusion practice but for whom patients 
have been identified, among which are samples with deleted 
or variant GPA, GPC, or Kell blood group glycoproteins. We 
use a urea method for screening for the Jk(a–b–) phenotype, 
as glycoproteins of the JK blood group system serve as a urea 
transport channel on the cell membrane of erythrocytes. In 
the meantime, specialized antisera, such as anti-Rh17, anti-
Dib, anti-Wrb, and anti-Vel, are used to screen for antigens for 
which respective antibodies frequently cause clinical hemolytic 
transfusion reactions and hemolytic disease of the fetus and 
newborn (HDFN).
Because the resource of rare antisera is limited, the 
identification of rare blood donors is more dependent on 
molecular testing. Previously, tests were performed by 
detecting single mutations of blood genes, whereas we now 
use multiplex polymerase chain reaction (PCR) systems with 
mixed DNA pools.1 
Our rare blood molecular screening program currently 
tests for 16 single nucleotide polymorphism sites including 
those associated with k–, s–, Co(a–), Yt(a–), and Fy(a–).
The DNA pool multiplex PCR screening method not only 
improves screening efficiency, but also largely reduces the cost. 
Furthermore, screening techniques utilizing blood-group gene 
chips also contribute to the acquisition of rare blood. We have 
carried out molecular testing on 450 donors in Shanghai using 
BloodChip reference chips (Grifols, Barcelona, Spain) and 
identified six donors with rare blood phenotypes, including 
s–, Di(b–), and VS+.
Distribution Features of Rare Blood Groups in the 
Chinese Population
The prevalence of blood group antigens vary among 
different races and populations. The Chinese population 
mainly includes the Mongoloid (99.2%) and the Caucasoid 
(0.8%). Han population is the main nationality in China, with 
1.1 billion people, which accounts for 91.6 percent of the total 
Chinese population. Racially, the Northern Han belong to the 
Far Eastern race, whereas the Southern Han are a transitional 
race between the Southern Asian race and Far Eastern race.
Because the prevalence of the D– type is as low as 
0.4 percent, challenges sometimes exist in supplying D– 
blood for clinical transfusion. According to the standard 
for blood product preparation and the guide for clinical 
blood transfusion in China, pre-transfusion examination 
includes the identification of the D type of both donors and 
recipients. Therefore, when blood transfusion services have 
excess D– blood, they will cryopreserve units with high-
concentration glycerol and store them at –85°C. In China, 
all the regional blood centers have frozen D– blood units in 
their inventory. Large blood centers in Shanghai, Beijing, and 
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Guangzhou supply 2000 units of D– blood per year to clinics, 
approximately 40 percent of which are cryopreserved. Unlike 
those of European or African descent, the D– population in 
those of Asian descent (especially those from the Far East 
region) is of the Del phenotype. In China, the Del phenotype 
accounts for 20 percent of all D– people. So far, there is no 
evidence in our clinical practice of transfusion showing that 
Del individuals as donors cause alloimmunization to D, and 
thus we consider it safe to supply Del blood to the clinic as D– 
blood. Similarly, the results from an investigation on immune 
antibodies in pregnancy among Del women also support our 
view, in which none of the Del pregnant women in 118 cases 
developed anti-D.2
Three Rhnull donors have been found in China, the blood 
from one of which has been provided to Rhnull patients. This 
Rhnull donor has normal RHD and RHCE, and the mutation of 
the RHAG may be causing the Rhnull phenotype.
Like the D– phenotype, Fy(a–) prevalence in the Chinese 
Han population is low (0.3%), and thus screening for Fy(a–) 
is also included in the screening program for rare donors in 
China. As Fy(a–) patients in China tend to produce anti-Fya in 
reaction to the corresponding antigen, there are more than 200 
Fy(a–) donors in our rare donor records to meet the clinical 
requirements for Fy(a–) blood. Diego is somewhat a special 
blood group in people of Asian descent; both Di(a+) and Di(b–) 
phenotypes are of higher prevalence in this population than 
in others. Clinically, anti-Dia and anti-Dib frequently result 
in transfusion reactions and HDFN; therefore, it is of great 
importance to screen for Di(b–) donors for Di(b–) patients.
Creation of a National Rare Blood Bank in China
Five years of screening has resulted in 1.5 million donors 
being screened, mostly using serology. Molecular screening is 
used for specific purposes. There are already over 1300 rare 
blood donors identified in the National Rare Blood Bank. Their 
information has been registered in the rare blood database 
and is available to medical professionals across China via a 
Web site.3 The phenotypes of the currently available units in 
the rare blood bank are summarized in Table 1; these units 
are from blood transfusion services across the country. After 
rare donors identified by these blood transfusion services 
are verified by the Shanghai Blood Center, the organizations 
register the donor information in the database and are 
responsible for keeping in regular contact with the donor. 
The methods of contact include sending messages to those 
rare blood donors for special holidays and organizing various 
activities for them as members of the donors’ club.
Clinical Application of Rare Blood Transfusion
In the most recent 5 years, 79 units of different types of 
rare blood have been supplied for clinical transfusion via the 
National Rare Blood Bank of China, including D– –, Rhnull, 
Jk(a–b–), and Fy(a–).
Inevitably, there is still a long way to go to find the ideal 
balance between the rare blood supply from our bank and the 
demands from the clinics. Currently, every year, 20 percent to 
30 percent of rare blood transfusion requests cannot be met. 
In 2015, there were two patients for whom we were unable to 
find the necessary type of rare blood: a 64-year-old female 
Di(b–) patient who needed transfusion because of anemia, 
and her serum contained anti-Dib, which may have been due to 
pregnancy; the other was a patient with sickle cell disease who 
was Fy(a–b–) with autoantibody. We transfused the Di(b–) 
patient with Di(a+b+) blood. The patient did not have severe 
adverse reactions during the transfusion, and the patient’s 
hemoglobin improved after transfusion. Fortunately, the 
Fy(a–b–) patient improved without transfusion, was released 
from the hospital after 4 weeks, and returned to the United 
States to continue treatment.
Table 1. Rare blood donors in China as of 2015
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Moreover, there are significant differences in regulations 
for blood product import and export in different countries, 
especially in infectious disease testing rules. Besides regular 
tests for human immunodeficiency virus, hepatitis B virus, 
and hepatitis C virus, tests for human T-lymphotropic virus, 
variant Creutzfeldt-Jakob disease, cytomegalovirus, and 
parvovirus B19 in donor blood are also mandatory in some 
countries. To some extent, the different requirements for 
infectious disease testing limit the distribution of rare blood to 
different countries.
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